• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Scilex touts data for novel lidocaine patch

December 5, 2016 By Sarah Faulkner

Scilex touts data for novel lidocaine patchSorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that its lidocaine patch, ZTlido, met primary and secondary endpoints in a pivotal study comparing the patch to Endo Pharmaceutical‘s Lidoderm patch. The data will be used to resubmit a new drug application to the FDA in mid-2017, the Malvern, Pa.-based company said.

The clinical trial evaluated Scilex’s 1.8% lidocaine patch to the 5.0% Lidoderm patch. The primary endpoint established comparative pharmacokinetics, while the secondary endpoint demonstrated bioequivalence between the 2 patches. ZTlido’s anhydrous patch contains only 36 mg of lidocaine, while Lidoderm holds 700 mg per patch.

The company is developing ZTlido to treat a severe neuropathic pain condition called post-herpetic neuralgia. Cancer patients, the elderly population, and HIV/AIDs patients are at the highest risk of developing PHN.

“We are very satisfied with the data from this pivotal study, and are now closer to meeting our objective with ZTlido, which is to provide an ultra-thin and pliable patch for patients to better manage the debilitating pain associated with PHN. Our market research shows that these attributes are key to enhancing patient compliance and potentially, enabling better treatment outcomes,” Scilex president Anthony Mack said in prepared remarks.

“Sorrento is pleased with the outcome of this study and believes, based on recent discussions with the FDA, that the data will be supportive of Scilex’s resubmission of its NDA to the FDA. In addition, the positive data is a key validation of Scilex’s novel technologies and ability to swiftly address important, unmet needs to ameliorate the treatment of acute and chronic conditions.  This was a key impetus for Sorrento’s acquisition of Scilex last month. We are confident that given its potential commercial differentiation, ZTlido will be able to gain a meaningful share of the $700 million lidocaine patch market,” Sorrento president & CEO Henry Ji added.

SRNE shares were trading at $5.55 apiece in afternoon activity, up 7.8%.

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals, Scilex Pharmaceuticals, Sorrento Therapeutics

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS